AxoGen (AXGN)
(Delayed Data from NSDQ)
$14.69 USD
+0.40 (2.80%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $14.69 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.69 USD
+0.40 (2.80%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $14.69 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum B VGM
Zacks News
Should You Continue to Retain MYGN Stock in Your Portfolio?
by Zacks Equity Research
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
PEN Stock to Gain From CE Mark Approval for its CAVT Technologies
by Zacks Equity Research
Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.
IINN Stock Gains on Second US Patent Approval for VORTX System
by Zacks Equity Research
Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.
PAHC Stock Gains From Innovation, Market Expansion Goal
by Zacks Equity Research
Phibro Animal Health's nutritional product offerings, such as OmniGen-AF and Animate, are being increasingly used in the global dairy industry.
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?
by Zacks Equity Research
QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.
Owens & Minor Stock to Gain From New Collaboration With Google Cloud
by Zacks Equity Research
OMI announces partnership with Google Cloud to enhance existing QSight capabilities.
Should You Continue to Retain OMCL Stock in Your Portfolio Now?
by Zacks Equity Research
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
LH Stock Expected to Gain From the Ballad Health Acquisition Deal
by Zacks Equity Research
Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.
HSIC Stock Likely to Get a Boost From New Henry Schein One Launches
by Zacks Equity Research
Henry Schein's dental software arm unveils Dentrix Eligibility offerings to elevate the insurance verification process.
CRL Stock May Benefit From New Neuroscience Research Collaboration
by Zacks Equity Research
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
by Zacks Equity Research
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
EW Stock Dips Following the Divestiture of Critical Care Wing
by Zacks Equity Research
Edwards completes the sale of its Critical Care operations and announces a $1 billion share repurchase program.
EW Stock to Benefit From Favorable RHEIA Trial Data on TAVI
by Zacks Equity Research
Edwards' first all-female TAVI Trial demonstrates favorable outcomes for women receiving Edwards valves.
What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases
by Zacks Equity Research
QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.
Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark
by Zacks Equity Research
BSX achieves CE Mark approval for the ACURATE Prime Aortic Valve System, its latest TAVR technology.
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for AxoGen (AXGN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 200% and 10.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of -27.45% and 0.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.